New pages

27 August 2026

• 19:4019:40, 27 August 2026 REDEMPLO- plozasiran injection, solution (hist | edit) [23,251 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) |indicationType=treatment |indication=for hypertriglyceridemia in adults with familial chylomicronemia syndrome (FCS), as an adjunct to diet. |adverseReactions=hyperglycemia, headache, nausea, and injection site reaction. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span st...")
• 19:2719:27, 27 August 2026 KOMZIFTI- ziftomenib capsule (hist | edit) [45,333 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=menin inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult patients who have no satisfactory alternative treatment options. |hasBlackBoxWarning=Yes |adverseReactions=aspartate aminotransferase increase, infection without an identified pathogen, potassium decreased, albumin decreased, alanine...")
• 18:4118:41, 27 August 2026 LYNKUET- elinzanetant capsule (hist | edit) [40,883 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=neurokinin receptor antagonist |indicationType=treatment |indication=moderate to severe vasomotor symptoms (VMS) due to menopause. |adverseReactions=headache, fatigue, gastroesophageal reflux disease, dizziness, nausea, and somnolence. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIA...")

26 August 2026

• 20:3820:38, 26 August 2026 JASCAYD- nerandomilast tablet, film coated (hist | edit) [45,041 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=phosphodiesterase 4 (PDE4) inhibitor |indicationType=treatment |indication=idiopathic pulmonary fibrosis (IPF) in adult patients, and progressive pulmonary fibrosis (PPF) in adult patients. |adverseReactions=diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness. |blackBoxWarningTitl...")
• 20:0120:01, 26 August 2026 RHAPSIDO- remibrutinib tablet (hist | edit) [30,531 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. |adverseReactions=nasopharyngitis, bleeding, headache, nausea and abdominal pain. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:<...")
• 19:5119:51, 26 August 2026 INLURIYO- imlunestrant tablet, film coated (hist | edit) [33,065 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. |adverseReactions=hemoglobin decreased, musculoskeletal pain, calcium...")

24 August 2026

• 18:3518:35, 24 August 2026 FORZINITY- elamipretide hydrochloride injection (hist | edit) [25,894 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=mitochondrial cardiolipin binder. |indicationType=treatment |indication=Barth syndrome in adult and pediatric patients weighing at least 30 kg, to improve muscle strength. |adverseReactions=injection site reactions. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult====Barth Syndrome...")
• 18:2018:20, 24 August 2026 WAYRILZ- rilzabrutinib tablet, film coated (hist | edit) [35,588 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=Bruton's tyrosine kinase (BTK) inhibitor |indicationType=treatment |indication=adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. |adverseReactions=diarrhea, nausea, headache, abdominal pain, and COVID-19. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<...")

22 August 2026

• 08:3608:36, 22 August 2026 SAndbox: JAF MS ECG (hist | edit) [0 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Multiple sclerosis}} {{CMG}}; {{AE}} {{Fs}} ==Overview== An electrocardiogram (ECG) is '''not used to diagnose multiple sclerosis (MS)''', and there are no ECG findings that are specific or diagnostic for MS. The diagnosis of MS is established using clinical findings together with appropriate paraclinical evidence, including MRI and, when appropriate, cerebrospinal fluid (CSF) biomarkers, according to the 2024 revision...")

20 August 2026

• 20:2420:24, 20 August 2026 Sandbox:JAF (hist | edit) [20,358 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Template:Multiple sclerosis}} {{CMG}}; {{AE}} {{Fs}} ==Overview== The symptoms of multiple sclerosis (MS) are variable and may involve vision, sensory function, motor function, coordination, cognitive impairment, mood, bowel and bladder function, sexual dysfunction, sleep, and fatigue. Common manifestations include Fatigue, mood pro...")
• 04:5704:57, 20 August 2026 Templete:ANG (hist | edit) [66 bytes] Aiden Nguyen (talk | contribs) (Created page with "Aiden Nguyen[mailto:aidennguyen7@gmail.com]")

15 August 2026

• 23:1223:12, 15 August 2026 BRINSUPRI- brensocatib tablet (hist | edit) [33,398 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Brensocatib |aOrAn=a |drugClass=dipeptidyl peptidase 1 (DPP1) inhibitor |indicationType=treatment |indication=non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older |adverseReactions=upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, hypertension. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBo...")
• 22:3722:37, 15 August 2026 DAWNZERA- donidalorsen injection, solution (hist | edit) [49,127 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Donidalorsen |aOrAn=a |drugClass=prekallikrein directed antisense oligonucleotide |indicationType=prophylaxis |indication=attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. |adverseReactions=injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort. |blackBoxWarningTitle='''<span style="color:#FF00...")
• 22:0322:03, 15 August 2026 HERNEXEOS- zongertinib tablet, film coated (hist | edit) [41,832 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Zongertinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. |adverseReactions=diarrhea, rash, hepatotoxicity, fatigue, nausea, musculoskelet...")

14 August 2026

• 16:3216:32, 14 August 2026 Sandbox: HAM (hist | edit) [14,417 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{SAI}} {{Tension headache}} ==Tension type headache medical therapy== Medical management of tension-type headache (TTH) consists of acute treatment with simple analgesics, preventive therapy for frequent or disabling headache, evidence-based behavioral interventions, and prevention of medication-overuse headache (MOH). Current evidence supports ibuprofen or acetaminophen as first-line acute therapy and amitriptyline as the b...")
• 06:2806:28, 14 August 2026 Vascular cognitive impairment and dementia historical perspective (hist | edit) [9,830 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} {{HAM}} ==Historical Perspective== ===Overview=== The concept of '''vascular cognitive impairment and dementia (VCID)''' has evolved through three broad eras: 19th-century recognition of discrete vascular brain lesions (Marie's ''état lacunaire''; Binswanger's subcortical white matter disease), a mid-20th-century "arteriosclerotic dementia" h...")
• 04:2404:24, 14 August 2026 Vascular cognitive impairment and dementia Overview (hist | edit) [17,040 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} HAM ==Overview== '''Vascular cognitive impairment and dementia (VCID)''' is cognitive impairment attributable predominantly to cerebrovascular disease, spanning a spectrum from mild vascular cognitive impairment (VCI) to vascular dementia (VaD), its most severe form.<ref name="Sachdev2026">{{cite journal...")
• 02:0202:02, 14 August 2026 Vascular cognitive impairment and dementia (hist | edit) [2,036 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} Person 1, Person 2, Your Name ==Overview== ==Historical Perspective== ==Classification== ==Pathophysiology== ==Causes== ==Type pa...")

13 August 2026

• 15:5215:52, 13 August 2026 MODEYSO- dordaviprone capsule (hist | edit) [45,937 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Dordaviprone |aOrAn=a |drugClass=protease activator |indicationType=treatment |indication=adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. |adverseReactions=fatigue, headache, vomiting, nausea, and musculoskeletal pain. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE...")
• 15:3315:33, 13 August 2026 VIZZ- aceclidine solution/ drops (hist | edit) [15,742 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Aceclidine |aOrAn=a |drugClass=cholinergic muscarinic agonist |indicationType=treatment |indication=presbyopia in adults. |adverseReactions=instillation site irritation, dim vision, and headache. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult====Presbyopia=== ====FDA-Labeled Indication...")
• 12:5612:56, 13 August 2026 PALSONIFY- paltusotine tablet, film coated (hist | edit) [38,274 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Paltusotine |aOrAn=a |drugClass=somatostatin receptor agonist |indicationType=treatment |indication=adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. |adverseReactions=diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis. |blackBoxWarningTitle='''<span...")

5 August 2026

• 13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy case studies (hist | edit) [25 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy future or investigational therapies (hist | edit) [16,766 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy cost-effectiveness of therapy (hist | edit) [14,005 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy follow-up and surveillance (hist | edit) [22,203 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy comparative therapies (hist | edit) [22,822 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy outcomes and prognosis (hist | edit) [21,364 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy periprocedural complications (hist | edit) [20,563 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy procedural technique and intraprocedural imaging (hist | edit) [20,797 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy pre-procedural imaging and assessment (hist | edit) [14,889 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy indications and contraindications (hist | edit) [18,948 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy pathophysiology of gradient reduction (hist | edit) [18,106 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy patient and anatomic selection (hist | edit) [14,891 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2213:22, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy historical perspective (hist | edit) [20,211 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 13:2213:22, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy overview (hist | edit) [10,219 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 11:4611:46, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy (hist | edit) [2,106 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{xyz}} '''To view the main page click here.''' {{CMG}}; {{AE}} {{Nehal}} ==Overview== ==Historical Perspective== ==Patient and Anatomic Selection== ==Pathophysiology of Gradient Reduction== ==Type page name here Indications a...")
• 11:1411:14, 5 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Future Therapies (hist | edit) [20,286 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 11:0911:09, 5 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Cost-Effectiveness (hist | edit) [8,313 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}} __NOTOC__ ==Cost-Effectiveness== Economic evidence for transcatheter edge-to-edge repair (TEER) in heart failure with reduced ejection fraction and secondary mitral regurgitation is derived predominantly from COAPT-based analyses comparing TEER plus guideline-directed medical therapy (GDMT) with GDMT alone. The results are model-based, payer-specific, and dependent on patient selection, device cost, hospitalization reduction, an...")

3 August 2026

• 19:1919:19, 3 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Follow-Up and Surveillance (hist | edit) [51,678 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
• 19:1019:10, 3 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) natural history, complications and prognosis (hist | edit) [30,115 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ ==Natural history, complications, and prognosis== ===Natural history during guideline-directed medical therapy=== Ventricular secondary mitral regurgitation (SMR) in heart failure with reduced ejection fraction (HFrEF) is a dynamic lesion whose severity may change substantially after optimization of guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT). In a prospective cohort of 2,254 ambulatory patients with...")